Efficacy of gastric per-oral endoscopic myotomy remains similar after failure of interventional techniques in refractory gastroparesis

•What is already known on this subject?Gastric per-oral endoscopic myotomy (G-POEM) is a new therapeutic option in refractory gastroparesis.However, the efficacy of the procedure after previous interventional techniques has been poorly assessed.•What are the new findings?The efficacy rate of G-POEM...

Full description

Saved in:
Bibliographic Details
Published inClinics and research in hepatology and gastroenterology Vol. 48; no. 9; p. 102481
Main Authors Chartier, Marion, Duboc, Henri, Moszkowicz, David, Dior, Marie, Le Gall, Maude, Coffin, Benoit, Soliman, Heithem
Format Journal Article
LanguageEnglish
Published France Elsevier Masson SAS 01.11.2024
Subjects
Online AccessGet full text
ISSN2210-7401
2210-741X
2210-741X
DOI10.1016/j.clinre.2024.102481

Cover

Loading…
More Information
Summary:•What is already known on this subject?Gastric per-oral endoscopic myotomy (G-POEM) is a new therapeutic option in refractory gastroparesis.However, the efficacy of the procedure after previous interventional techniques has been poorly assessed.•What are the new findings?The efficacy rate of G-POEM in 32 patients previously treated by pyloric dilation and/or gastric electrical stimulation was similar to that in 16 patients naïve to instrumental technique (50.0% vs 56.3%; p=0.41).The complication rate was also similar.•How might it impact on clinical practice in the foreseeable future?G-POEM remains a safe and effective option even after the failure of previous instrumental procedures Gastric per-oral endoscopic myotomy (G-POEM) is a new therapeutic option for the treatment of refractory gastroparesis. However, the outcome of G-POEM after the failure of gastric electrical stimulation (GES) or other pylorus-targeting therapies has been poorly reported. Data were collected from patients referred for G-POEM for refractory gastroparesis. The efficacy in patients with previous interventional techniques was compared to patients naïve to instrumental technique. The primary endpoint was the 6-month clinical success rate, defined as at least a 1-point decrease in the Gastroparesis Cardinal Symptom Index (GCSI). Among 48 patients referred for G-POEM, 32 patients had previous instrumental treatments (66%): 15 (31%) had GES, and 17 (35%) had pyloric endoscopic dilation or toxin injection. The technical success rate was 100%. At 6 months, clinical success was achieved in 25/48 patients (52%) and the GCSI decreased from 3.38 (2.94–3.95) to 2.25 (1.11–3.36) (p < 0.001). The 6-month success rate was similar in patients with or without previous instrumental treatment (50.0% vs 56.3%; p = 0.41). The complication rate was also similar in the two groups (6.3% vs 12.5%; p = 0.59), with only one severe adverse event. The only predictive factor for success at 6 months was a higher body mass index (OR = 1.14 [1.01–1.32]; p = 0.05). G-POEM is safe and remains effective after GES or previous pyloric treatment failure, with 50% efficacy at 6 months. The therapeutic strategy in refractory gastroparesis remains to be defined.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2210-7401
2210-741X
2210-741X
DOI:10.1016/j.clinre.2024.102481